Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Neoplasms 2Lymphoma 2Recurrence 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Drugs, Investigational × Lymphoid × Clear all
NCT05972720 2025-05-15

FIRCE-1

CARGO Therapeutics

Phase 2 Terminated
101 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04111107 2024-07-03

Precision Medicine for Patients With Identified Actionable Mutations

Wake Forest University Health Sciences

Phase 2 Terminated
45 enrolled 13 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡